PharmaResearch Co., Ltd. (KOSDAQ:214450)

PharmaResearch Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	135,790	165,348	67,245	72,931	41,674	26,715
Short-Term Investments	291,839	230,480	56,549	67,989	2,000	8,981
Trading Asset Securities	53,429	41,523	36,505	43,423	113,123	43,571
Cash & Short-Term Investments	481,058	437,351	160,298	184,343	156,798	79,267
Cash Growth	133.44%	172.84%	-13.04%	17.57%	97.81%	14.83%
Accounts Receivable	48,663	38,460	31,400	32,304	27,741	22,827
Other Receivables	3,476	4,052	3,301	2,757	975.32	873.4
Receivables	65,008	56,564	35,998	36,234	30,490	26,343
Inventory	60,693	57,325	50,232	24,453	17,342	20,781
Prepaid Expenses	-	950.54	1,191	667.94	701.54	373.73
Other Current Assets	6,151	2,351	8,746	1,647	1,460	639.42
Total Current Assets	612,909	554,542	256,465	247,345	206,792	127,404
Property, Plant & Equipment	164,556	147,313	123,061	117,960	109,481	94,046
Long-Term Investments	84,224	85,811	99,107	40,718	44,911	42,511
Goodwill	13,856	13,856	11,652	13,810	16,764	12,492
Other Intangible Assets	19,580	18,309	18,821	22,720	24,825	26,233
Long-Term Deferred Tax Assets	4,072	8,557	4,476	8,667	3,166	3,162
Long-Term Deferred Charges	1,077	1,227	1,502	1,297	1,200	578.13
Other Long-Term Assets	20,961	23,745	16,259	21,105	15,715	13,407
Total Assets	923,238	855,701	535,281	478,055	427,647	319,831
Accounts Payable	9,138	11,081	2,831	3,527	2,939	1,876
Accrued Expenses	-	1,493	974.34	860.08	702.95	533.87
Short-Term Debt	100	9,359	32,345	18,867	18,873	17,854
Current Portion of Long-Term Debt	7,443	20	33.3	87.4	726.52	610
Current Portion of Leases	2,099	2,421	628.25	1,620	1,161	1,117
Current Income Taxes Payable	18,648	23,355	11,357	10,136	6,851	6,222
Current Unearned Revenue	727.43	7.89	27.69	11.36	-	-
Other Current Liabilities	40,844	34,400	17,703	19,144	16,751	7,637
Total Current Liabilities	79,000	82,137	65,899	54,253	48,005	35,849
Long-Term Debt	198,962	195,865	970.72	45,359	43,385	10,505
Long-Term Leases	1,012	1,121	329.91	835.48	1,466	2,324
Long-Term Deferred Tax Liabilities	1,808	2,156	2,794	3,741	4,514	4,746
Other Long-Term Liabilities	2,174	2,485	1,911	1,648	1,175	1,133
Total Liabilities	285,105	285,580	73,087	106,399	99,288	55,420
Common Stock	5,255	5,255	5,160	5,056	5,056	4,895
Additional Paid-In Capital	198,076	197,312	175,428	157,582	152,413	133,405
Retained Earnings	410,569	343,061	260,787	190,862	154,018	112,615
Treasury Stock	-	-4,638	-4,638	-5,260	-5,260	-5,260
Comprehensive Income & Other	-2,338	-1,588	-3,633	-4,737	-785.15	-232.35
Total Common Equity	611,563	539,402	433,104	343,503	305,442	245,423
Minority Interest	25,912	30,038	29,091	28,153	22,917	18,989
Shareholders' Equity	638,132	570,121	462,195	371,656	328,359	264,411
Total Liabilities & Equity	923,238	855,701	535,281	478,055	427,647	319,831
Total Debt	209,617	208,786	34,307	66,768	65,611	32,410
Net Cash (Debt)	271,441	228,565	125,991	117,575	91,187	46,857
Net Cash Growth	58.72%	81.41%	7.16%	28.94%	94.61%	-2.56%
Net Cash Per Share	25139.78	22202.30	11932.17	11785.88	9070.92	4928.76
Filing Date Shares Outstanding	10.39	10.39	10.2	9.98	9.98	9.65
Total Common Shares Outstanding	10.39	10.39	10.2	9.98	9.98	9.65
Working Capital	533,909	472,405	190,566	193,092	158,787	91,555
Book Value Per Share	58862.69	51917.28	42459.18	34433.24	30617.96	25424.37
Tangible Book Value	578,127	507,238	402,631	306,974	263,854	206,698
Tangible Book Value Per Share	55644.47	48821.45	39471.79	30771.48	26449.11	21412.71
Land	22,450	21,051	18,617	18,617	14,064	14,064
Buildings	81,832	79,470	81,472	80,151	52,235	52,135
Machinery	58,052	52,305	41,375	30,766	27,162	22,544
Construction In Progress	43,836	31,510	12,459	12,200	32,985	16,386

Source: S&P Global Market Intelligence. Standard template. Financial Sources.